MEDDEV 2.7/1 Rev.4 Under EU MDR: What Still Matters and What Has Changed
MEDDEV 2.7/1 Revision 4 has shaped European clinical evaluation practice since 2016. It introduced a much more structured approach to identifying, appraising and analysing clinical data and remains deeply embedded in the way many manufacturers build their Clinical Evaluation Reports.
But the regulatory framework has changed.
MEDDEV 2.7/1 Rev.4 was written for the Medical Devices Directive (MDD) and Active Implantable Medical Devices Directive (AIMDD). Under the EU Medical Device Regulation (MDR), the legal requirements for clinical evaluation now come from Article 61 and Annex XIV, supported by subsequent MDCG guidance.
That does not make MEDDEV irrelevant. Selected parts of its methodology remain useful under MDR and have been expressly identified as such by MDCG 2020-6.
The important question is therefore not whether manufacturers should still “follow MEDDEV”.
It is which parts remain useful, where the MDR has moved beyond it, and which source takes precedence when they differ.
MEDDEV 2.7/1 Rev.4 at a Glance
Authority
Legacy European Commission guidance developed under the MDD/AIMDD
Published
June 2016
Current Status
Historical/legacy methodology; selected sections remain relevant under MDR where compatible with current legislation and guidance
Read Alongside
MDR Article 61 and Annex XIV; MDCG 2020-5, MDCG 2020-6 and MDCG 2020-13
The Headline
MEDDEV 2.7/1 Rev.4 is no longer the governing framework for clinical evaluation in the EU.
The MDR is.
Article 61 requires manufacturers to plan, conduct and document clinical evaluation in accordance with Article 61 itself and Annex XIV Part A. Annex XIV defines the current requirements for the Clinical Evaluation Plan, identification and appraisal of clinical data, generation of additional evidence where needed, analysis and documentation. However, MEDDEV remains methodologically important.
MDCG 2020-6 specifically identifies sections of MEDDEV 2.7/1 Rev.4 that remain relevant under MDR when applying its guidance to legacy devices. Those sections include:
evaluator qualifications;
identification of pertinent clinical data;
appraisal of clinical data;
analysis of clinical data;
sources of literature;
literature search and review protocols;
examples of data lacking sufficient scientific validity;
benefit-risk, performance and undesirable side-effect assessment; and
the MEDDEV checklist for release of a CER. Public Health
So MEDDEV remains a valuable methodological resource.
It should not, however, be treated as though the MDR never replaced the Directives it was written to support.
What You Need to Know
The MDR takes precedence.
Where MEDDEV terminology, requirements or assumptions differ from Regulation (EU) 2017/745 or current MDCG guidance, the MDR framework controls..
MEDDEV still contains useful methodology.
MDCG 2020-6 explicitly preserves the relevance of selected sections dealing with evaluator competence, literature identification, appraisal, analysis and benefit-risk assessment. Public Health.
Literature review should be planned and reproducible.
MEDDEV Appendix A5 remains a useful reference for structuring literature search and review protocols. It does not, however, mandate PICO specifically. PICO may be a useful framework for particular clinical questions, but it is a methodological choice rather than a universal MEDDEV requirement.
Finding evidence and appraising evidence are different activities.
MEDDEV's staged approach to identification, appraisal and analysis remains highly useful under MDR.
Equivalence has moved on substantially.
The MDR itself now defines the technical, biological and clinical criteria for equivalence, while MDCG 2020-5 and MDCG 2023-7 provide more current guidance. MEDDEV should not be used as the controlling equivalence source.
A compliant CER is not simply a MEDDEV-formatted document.
Under MDR, the CER needs to sit within the wider Annex XIV clinical-evaluation system, including the CEP, sufficient clinical evidence, PMS and PMCF.
Does MEDDEV 2.7/1 Rev.4 still apply under MDR?
Not in the same way it did under the Directives.
MEDDEV 2.7/1 Rev.4 describes itself as non-legally binding guidance relating to the application of the MDD and AIMDD. Public Health It was not written as guidance to Regulation (EU) 2017/745.
For an MDR clinical evaluation, the primary hierarchy is therefore:
MDR Article 61 and Annex XIV → applicable current MDCG guidance → compatible legacy methodology such as relevant parts of MEDDEV 2.7/1 Rev.4.
That last layer still matters.
MDCG 2020-6 formally identifies parts of MEDDEV that remain relevant under MDR because they contain useful information about how clinical-evaluation activities can be performed. Public Health
That gives manufacturers a sensible way to use MEDDEV today: as a methodological resource, not as a substitute for the MDR.
This distinction is particularly important for legacy CERs written originally under the MDD.
A document may closely follow MEDDEV 2.7/1 Rev.4 yet still contain significant MDR gaps because it does not address the additional requirements introduced by Article 61, Annex XIV or later MDCG guidance.
Still relying on MEDDEV 2.7/1 Rev.4 for your clinical evaluation?
A 30-minute Clinical Evaluation Discovery Call gives you an opportunity to discuss your CER, identify potential MDR gaps and understand where legacy methodology may need updating.
What it Means Commercially
The practical risk is not usually that a manufacturer has ignored MEDDEV completely.
It is that a clinical evaluation has been maintained within an MDD-era framework while the regulatory question around it has changed.
A mature legacy CER may contain a literature search, appraisal tables, equivalence discussion, evaluator qualifications and benefit-risk conclusions. Those elements can all still be valuable.
But the MDR may now require more around them.
The Clinical Evaluation Plan may need strengthening. Equivalence may need to be reassessed against MDR Annex XIV and MDCG 2020-5. Clinical evidence sufficiency may need explicit justification. PMS and PMCF evidence may need better integration. Clinical benefits and outcome parameters may need clearer definition.
That means wholesale rewriting is not always the correct answer.
Where the underlying methodology and evidence are sound, the more proportionate approach may be to identify which parts remain defensible, identify the genuine MDR gaps and remediate those systematically.
Conversely, changing the headings on an old MEDDEV CER and calling it an MDR CER does not resolve an underlying evidence or methodology problem.
What still Matters for Your Clinical Evaluation
Clinical Evaluator Competence
Section 6.4 of MEDDEV remains particularly relevant.
MDCG 2020-6 expressly identifies “Who should perform the clinical evaluation?” as one of the MEDDEV sections that remains useful under MDR. Public Health
The underlying principle is straightforward: clinical evaluation requires appropriate scientific, clinical, device and regulatory expertise, and the manufacturer should be able to demonstrate why the evaluators are competent to perform the work.
This remains relevant in practice because the quality of a clinical evaluation depends not only on the evidence collected but also on the expertise used to interpret it.
Notified body clinical-evaluation assessment under MDR also examines the manufacturer's clinical-evaluation process and documentation rather than treating the CER as a standalone narrative. MDCG 2020-13 provides the current assessment framework used to structure that review. Public Health
Systematic Identification of Clinical Data
MEDDEV's Stage 1 approach to identifying pertinent data remains useful.
Clinical evaluation should consider the complete relevant evidence base rather than selectively citing studies that support the desired conclusion.
That principle is now also embedded directly in Annex XIV, which requires manufacturers to identify available clinical data relevant to the device and intended purpose, identify gaps through systematic scientific literature review and consider both favourable and unfavourable evidence. Eur-Lex
MEDDEV therefore remains helpful for the method, while Annex XIV supplies the present legal requirement.
Literature Search and Review Protocols
MEDDEV Appendix A5 remains a useful methodological reference for planning and documenting literature searches.
A defensible literature review should make it possible to understand how evidence was identified. That normally means documenting matters such as:
the clinical questions being addressed;
information sources and databases;
search terms and strategies;
date ranges;
inclusion and exclusion criteria;
screening methodology; and
the rationale for important methodological decisions.
The objective is reproducibility and transparency.
A predefined framework such as PICO may be useful where appropriate, particularly when a clinical question naturally separates into population, intervention, comparator and outcome.
But MEDDEV does not mandate PICO as the universal structure for a clinical literature search.
The methodology should fit the clinical question.
Appraisal of Clinical Data
One of MEDDEV's most enduring contributions is the distinction between identifying data and deciding what evidential weight it deserves.
MDCG 2020-6 specifically retains MEDDEV Section 9 and Appendix A6 as relevant resources for clinical-data appraisal under MDR. Public Health
Appraisal should consider both relevance and scientific validity.
A publication may be methodologically strong but only weakly applicable to the device under evaluation. Conversely, highly relevant evidence may have methodological limitations that reduce the confidence that can be placed in its conclusions.
Simply listing publications therefore does not amount to clinical evaluation.
The evidence needs to be critically evaluated before it can be relied upon.
Analysis and Benefit-Risk Conclusions
MEDDEV's Stage 3 analysis framework also remains useful.
The objective is not to produce an inventory of studies but to integrate the evidence into defensible conclusions concerning clinical safety, performance and benefit-risk.
MDCG 2020-6 retains MEDDEV's analysis section and relevant benefit-risk appendices as useful under MDR, while warning that references to the MDD within those sections need to be replaced by the applicable MDR requirements. Public Health
That qualification is important.
The analytical discipline remains useful. The regulatory test against which the analysis is performed has changed.
What the MDR has Changed
The Legal Framework
Under MEDDEV, clinical evaluation was being performed within the framework of the MDD or AIMDD.
Under MDR, Article 61 expressly requires manufacturers to specify and justify the level of clinical evidence necessary for their device and to plan, conduct and document the evaluation according to Article 61 and Annex XIV. Eur-Lex
Annex XIV also makes the Clinical Evaluation Plan an explicit part of the evaluation process and defines the identify → appraise → generate → analyse methodology in legislation.
A MEDDEV-compliant methodology therefore does not by itself demonstrate MDR compliance.
Equivalence
MEDDEV Rev.4 contained detailed equivalence methodology and helped establish the technical, biological and clinical framework.
The MDR subsequently incorporated equivalence directly into Annex XIV and imposed its own requirements, including sufficient access to the data needed to justify the equivalence claim. Eur-Lex
MDCG 2020-5 and MDCG 2023-7 then developed those expectations further.
For an MDR clinical evaluation, equivalence should therefore be assessed principally against the MDR and current MDCG guidance, not against MEDDEV alone.
Our separate guide, MDCG 2020-5: How to Demonstrate Equivalence Under EU MDR, examines that distinction in detail.
Clinical Evidence Sufficiency
MEDDEV provides useful methodology for evaluating clinical evidence.
The MDR goes further by requiring the manufacturer to specify and justify the level of clinical evidence necessary to demonstrate conformity, taking account of the characteristics and intended purpose of the device. Eur-Lex
For legacy devices, MDCG 2020-6 provides further guidance on assessing whether the available clinical evidence is sufficient.
That means the question is not merely whether an appropriate evaluation process has been followed.
The manufacturer must also be able to justify why the resulting evidence base is enough.
CEP and Lifecycle Requirements
The MDR places clinical evaluation explicitly within a lifecycle framework.
Annex XIV requires a Clinical Evaluation Plan to be established and updated, while Article 61 links ongoing clinical evaluation to data arising from PMCF and PMS.
The clinical evaluation is therefore no longer best understood as a report refreshed periodically in isolation.
The CEP, CER, PMS, PMCF, risk management and clinical development strategy need to remain connected.
MEDDEV anticipated some of this lifecycle thinking, but Annex XIV now provides the controlling structure.
Where Manufacturers Commonly Get this Wrong
Treating MEDDEV as current law
MEDDEV is guidance, not legislation, and it was written for Directives that have been replaced for MDR devices.
Citing MEDDEV throughout a CER without addressing MDR Article 61, Annex XIV and applicable MDCG guidance can therefore create the appearance of a clinical-evaluation methodology that has not been fully transitioned.
Discarding MEDDEV completely
The opposite response is also unhelpful.
Some of MEDDEV's methodology remains extremely useful and is expressly referenced by current MDCG guidance.
Discarding established literature-search, appraisal, evaluator-competence and analysis methodology simply because the document predates MDR risks losing good scientific practice unnecessarily.
Assuming PICO is mandatory
A systematic literature review needs a clear, predefined methodology.
That does not mean every clinical-evaluation search must be forced into a PICO structure.
The framework should reflect the actual evidence question being asked.
Using a compliant structure with an inadequate method
A CER can contain all the expected headings and still fail to demonstrate a robust clinical evaluation.
The critical issue is whether the evidence was identified systematically, appraised appropriately and analysed in a way that supports the conclusions.
This is one reason MEDDEV remains valuable: at its best, it describes how to evaluate evidence, not simply what headings a CER should contain.
Carrying MDD-era equivalence forward unchanged
An equivalence assessment that was acceptable under an MDD-era MEDDEV framework should not simply be copied into an MDR CER.
The MDR criteria and subsequent MDCG guidance now control the assessment.
Treating the literature review as the entire clinical evaluation
Literature is only one potential clinical-data source.
The MDR clinical evaluation must consider the relevant evidence base as a whole, including applicable clinical investigations, device-specific data, PMS and PMCF information and other relevant evidence.
A technically sophisticated literature review cannot compensate for missing clinical evidence elsewhere.
Priority Actions
If your CER still relies heavily on MEDDEV 2.7/1 Rev.4:
1. Establish the regulatory hierarchy. Make sure MDR Article 61 and Annex XIV are treated as the primary requirements, with current MDCG guidance applied where relevant.
2. Retain useful MEDDEV methodology. Do not remove established literature-search, appraisal or analysis methods merely because their origin is MEDDEV.
3. Review the CEP separately. Confirm that it meets Annex XIV Part A rather than assuming a MEDDEV-era evaluation plan is sufficient.
4. Review literature methodology for transparency and reproducibility. Check that the clinical questions, search methods, selection criteria and appraisal methods are documented and justified.
5. Reassess equivalence against the MDR. Do not rely solely on the MEDDEV equivalence assessment.
6. Evaluate clinical evidence sufficiency explicitly. Determine whether the available evidence is enough for the device and intended purpose rather than assuming that the existence of published data establishes sufficiency.
7. Check the lifecycle interfaces. Ensure PMS and PMCF outputs genuinely feed back into the clinical evaluation and risk management process.
8. Avoid a formatting-only remediation. If the problem lies in evidence identification, appraisal or sufficiency, changing the CER structure will not solve it.
SciMed Perspective
MEDDEV 2.7/1 Rev.4 is most useful today when it is neither over-promoted nor discarded.
Treating it as the current regulatory rulebook gives it authority it no longer has.
Ignoring it entirely throws away a substantial body of useful clinical-evaluation methodology.
The better approach is to separate regulatory authority from methodological value.
The MDR tells manufacturers what the current clinical-evaluation system must achieve. Current MDCG guidance develops particular aspects of that system. MEDDEV can still help with some of the practical scientific methods used to get there.
That distinction is especially useful when reviewing legacy CERs.
The right question is rarely, “Do we need to rewrite this because it references MEDDEV?”
It is, “Which parts of the existing evaluation remain scientifically and regulatorily defensible, and where has the MDR created a genuine gap?”
That usually leads to a more proportionate remediation strategy.
How SciMed Can Help
SciMed supports manufacturers across the Clinical Evaluation lifecycle, from Clinical Evaluation Plans and State-of-the-Art reviews through literature identification and appraisal to Clinical Evaluation Reports and ongoing maintenance.
For legacy documentation, we can assess an existing clinical evaluation against the current MDR framework, distinguish sound legacy methodology from genuine regulatory gaps and identify where additional analysis, evidence or remediation is required.
Where the position is uncertain, SciMed's Clinical Evaluation Gap Analysis provides a structured review of the clinical-evaluation system before those gaps emerge during notified body assessment.
Primary Sources & Related Guidance
Primary Legacy Source
MEDDEV 2.7/1 Revision 4, Clinical Evaluation: A Guide for Manufacturers and Notified Bodies under Directives 93/42/EEC and 90/385/EEC, European Commission, June 2016. Public Health
Current Legal Framework
Regulation (EU) 2017/745, Article 61 and Annex XIV Part A. Eur-Lex
Related Current Guidance
MDCG 2020-6, Guidance on Sufficient Clinical Evidence for Legacy Devices, including its Appendix I identification of MEDDEV sections that remain relevant under MDR. Public Health
MDCG 2020-13, Clinical Evaluation Assessment Report Template, which provides a current MDR framework for notified body assessment of clinical evaluation. Public Health
MDCG 2020-5, Clinical Evaluation – Equivalence.
MDCG 2023-7, Guidance on exemptions from the requirement to perform clinical investigations and sufficient levels of access to data needed to justify claims of equivalence.
Need support with an equivalence or wider Clinical Evaluation issue?
Continue the Clinical Evaluation Source Series
This article is part of SciMed's Clinical Evaluation source series.
Related articles:
MDR Annex XIV: What It Requires for Clinical Evaluation and PMCF
The legal framework governing clinical evaluation and PMCF under MDR.MDCG 2020-5: How to Demonstrate Equivalence Under EU MDR
Our guide to the current MDR requirements for using equivalent-device clinical data.MDCG 2020-6: Clinical Evidence for Legacy Devices and the WET Route
Next in the series: what sufficient clinical evidence means for legacy devices and how well-established technology should be approached.
